Moderna (NASDAQ:MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

Moderna reiterated its full-year 2025 product sales forecast of $1.5 billion to $2.5 billion, with most expected in the ...

Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to ...

The U.S. FDA is planning to require all new vaccines to undergo placebo-controlled trials before approval. Read more here.